VSee Health Reports Third Quarter 2024 Revenue Up 131% Year-over-Year SAN JOSE, Calif.

VSee Health Reports Third Quarter 2024 Revenue

Up 131% Year-over-Year

SAN JOSE, Calif. -- November 15, 2024 --

VSee Health, Inc. (Nasdaq: VSEE), a provider of comprehensive telehealth services that customize workflow streams and enhance

patient care, today provided a business update and reported financial results for the three and nine months ended September 30, 2024.

Financial & Business Highlights

Management Commentary

"This quarter marks a transformative moment

for VSee Health, the completion of our first full quarter post-merger. The integration of VSee Lab and iDoc Virtual Telehealth Solutions

has solidified our position in delivering scalable, tailored telehealth solutions," said Imo Aisiku, M.D., co-CEO and Chairman of

VSee Health. "We believe our combined company is uniquely positioned to address critical challenges in healthcare, from expanding

access in underserved communities to optimizing workflows for enterprise-level clients. This period has demonstrated the resilience of

our platform and our capacity to drive meaningful impact."

"We believe that our ability to combine fast

customization, enterprise scalability, and robust security is what sets us apart in the crowded telehealth space. This quarter's strategic

initiatives and partnerships, including the launch of programs addressing obesity, maternal health disparities, and veteran care, exemplify

our commitment to delivering scalable solutions that improve lives while creating long-term value for our stakeholders," added Milton

Chen, Ph.D., co-CEO of VSee Health.

Third Quarter Financial Results

Third quarter consolidated financial statements

include the accounts of VSee Health, Inc. and its subsidiaries, VSee Lab, Inc. and iDoc Virtual Telehealth Solutions, Inc.,

which are both 100% wholly owned subsidiaries of VSee Health following the business combination on June 24, 2024.

Revenue was $3.4 million for the third quarter

of 2024, compared to $1.5 million for the third quarter of 2023, an increase of 131%. The increase was primarily driven by $1.1 million

or 100% of revenue from the acquisition of iDoc in the second quarter, as well as higher technical and engineering fees, and professional

and other fees and. Technical and engineering fees increased by 267% due to a higher volume of engineering, customizations and integration

services provided to the U.S. Department of Health and Human Services and existing customers. Professional and other fees increased by

40% due to higher project management services primarily to a recently signed significant client. Subscription revenue also increased 9%

due to higher usage volumes.

Operating expenses for the third quarter of 2024

increased by $58.2 million. The increase was driven by one-time goodwill impairment charges of $55.0 million. The increase was also driven

by higher general and administrative expense, primarily from amortization expense and an increase in expenses related to the acquisition

of iDoc, as well as transaction related expenses from the recapitalization and acquisitions of DHAC and iDoc, primarily for professional

and advisory service fees.

Net loss for the third quarter of 2024 was $51.8

million, compared to a net loss of $0.1 million for the third quarter of 2023. The increase was primarily driven by one-time goodwill

impairment charges of $55.0 million, and a $0.7 million loss on extinguishment related to note conversions and shares issued to vendors.

These were partially offset by a $5.7 million gain on the change in fair value of debt and derivative financial instruments.

Nine Month Financial Results

Revenue was $6.6 million for the nine months ended

September 30, 2024, compared to $4.3 million for the nine months ended September 30, 2023, an increase of $2.2 million or 51%.

The increase was primarily driven by 100% of revenue from the acquisition of iDoc in the second quarter, as well as higher technical and

engineering fees, and professional and other fees. Technical and engineering fees increased by 161% due to a higher volume of customizations,

engineering, and integration services for a recently signed significant client and existing customers. Professional and other fees increased

by 50% due to increased project management services, higher patient visits, and higher hardware purchases from new customers during the

second quarter. These increases were offset by a 2% decline in subscription revenue due to the churned enterprise customers in 2024, as

some clients gradually shifted back to face-to-face consultations.

Operating expenses for the nine months ended September 30,

2024 increased by $58.6 million to $63.0 million. The increase was driven by one-time goodwill impairment charges of $55.0 million, as

well as higher general and administrative expenses, primarily from amortization expense and an increase of expenses related to the acquisition

of iDoc. Additionally, transaction expenses from the recapitalization and acquisitions of DHAC and iDoc contributed to the increase, primarily

for professional and advisory service fees.

Net loss for the nine months ended September 30,

2024, was $52.1 million, compared to a net loss of $1.0 million for the same period in 2023. The increase was primarily driven by one-time

goodwill impairment charges of $55.0 million, $1.6 million initial fair value loss on the Quantum Note, and $0.7 million loss on extinguishment

related to note conversions and shares issued to vendors. These were partially offset by a $6.3 million gain on the change in fair value

of debt and derivative financial instruments.

As of September 30, 2024, VSee Health had

cash of $2.3 million.

Pro Forma Financial Results

The unaudited pro forma financial information

in the tables below summarizes the combined results of VSee Health's operations and iDoc's operations, as though the acquisition of iDoc

had been completed as of the beginning of 2023.

Proforma total revenues for the third quarter

of 2024 were $3.4 million compared with $3.1 million for the third quarter of 2023. Proforma total revenues for the nine months ended

September 30, 2024, were $9.2 million compared with $9.4 million for the same period of 2023.

The proforma net loss for the third quarter of

2024 was $0.4 million, or $(0.02) per share, compared with a net loss of $1.3 million, or $(0.09) per share, for the third quarter of

2023. The proforma net loss for the nine months ended September 30, 2024, was $2.4 million, or $(0.16) per share, compared with a

net loss of $3.4 million, or $(0.24) per share, for the same period of 2023.

The following table summarizes the pro forma financial information:

VSee Health's AI telehealth platform is the fastest

way for enterprises to go from ideation to market go-live. Field-hardened on over 1.5M HIPAA-compliant video encounters every month, its

customizable telehealth building blocks each meet stringent security standards, and are ready to scale. VSee Health has deployed services

in over 50 countries, including Iraq, Syria, Marshall Islands and El Salvador. Its clients include NASA Space Station, US Department of

Health and Human Services, McKesson, Magellan, DaVita, GE, countless startups, and the entire country of Qatar.

VSee Health also provides tailored solutions for

critical shortage areas such as critical care and teleradiology. It is committed to empowering high quality healthcare access and reducing

physician burnout and workforce shortages through its telehealth technology. For more information, please visit www.vseehealth.com.

Forward-Looking Statements

Matters discussed in this news release that are

not statements of historical or current facts, including but not limited to those relating to VSee Health's ability to improve healthcare

access and provider efficiencies, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform

Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause performance

or achievements to be materially different from historical results or from any future performance or achievements expressed or implied

by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. More information

on risk factors relating to VSee Health and its technology and billing services is included from time to time in the "Cautionary

Note Regarding Forward-Looking Statements," "Risk Factors" and "Management's Discussion and Analysis of Financial

Condition and Results of Operations" sections of VSee Health's periodic and current filings with the SEC, which are also made available

on VSee Health's website at www.vseehealth.com. Forward-looking statements speak only as of the date they are made, and VSee Health undertakes

no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise

that occur after that date, or otherwise

CONDENSED CONSOLIDATED BALANCE SHEETS

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER

30, 2024, AND 2023 (UNAUDITED)